SRPT · CIK 873303
What Sarepta Therapeutics, Inc. told the SEC could break it.
Sarepta's register leans heavily on its dependence on outside parties to make and validate what it sells: it relies entirely on third-party contract manufacturers for every commercial product and candidate, and on a single third party to develop and maintain the companion diagnostic that ELEVIDYS needs. Layered on top is regulatory and clinical uncertainty — its ESSENCE confirmatory trial missed its primary endpoint, putting the accelerated approvals of AMONDYS 45 and VYONDYS 53 at risk, and the pending BIOSECURE Act could force it out of arrangements with China-based research providers — alongside secured 2030 debt it may struggle to repay or refinance amid near-term operating losses.
5 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- BIOSECURE Act / China-based CRO dependencemedium
Some early-stage research and pre-clinical providers are in China; the pending BIOSECURE Act could force Sarepta to exit arrangements with China-based 'biotechnology companies of concern' and transition to alternatives.
“If adopted, the BIOSECURE Act could cause us to seek to exit some or all of our arrangements with China-based service providers determined to be “biotechnology companies of concern” and transition these services to alternative companies.”
- ESSENCE confirmatory trial missed primary endpoint (accelerated-approval risk for AMONDYS 45 / VYONDYS 53)medium
The ESSENCE confirmatory trial intended to verify clinical benefit of AMONDYS 45 and VYONDYS 53 did not show statistical significance on its primary endpoint, creating risk to these accelerated-approval products' post-marketing requirements.
“On November 3, 2025, we announced top-line results from our ESSENCE trial, a confirmatory trial intended to verify the clinical benefits of AMONDYS 45 and VYONDYS 53. The topline results did not show statistical significance on the study's primary endpoint.”
SEC filing →As of 2026
Liquidity & debt
- secured Credit Agreement (due 2030) and 4.875% 2030 Notes amid operating lossesmedium
Sarepta carries a secured Credit Agreement (maturing Feb 13, 2030, secured by substantially all assets, with quarterly financial covenants) plus 4.875% 2030 convertible notes, and may lack sufficient funds to repay or refinance amid near-term operating losses.
“We may not have sufficient funds, and may be unable to arrange for additional financing, to pay the amounts due under or refinance any indebtedness outstanding under the Credit Agreement, which is repayable on the maturity date, February 13, 2030.”
SEC filing →As of 2026
Sole-source dependency
- single third party for ELEVIDYS companion diagnostic testmedium
Sarepta relies on a single third party to develop, manufacture, and maintain regulatory approval for the diagnostic tests necessary for ELEVIDYS; any delay or failure could materially harm the business.
“For example, with respect to ELEVIDYS, we rely on a third party to develop, manufacture, obtain and maintain regulatory approval for necessary diagnostic tests for ELEVIDYS.”
SEC filing →As of 2026
Supplier concentration
- dependence on third-party CMOs for all product manufacturingmedium
Sarepta relies entirely on third-party contract manufacturers (CMOs) to make its commercial products and product candidates and depends on them for continued cGMP compliance; failure or loss could disrupt commercial and clinical supply.
“We currently rely on third parties to manufacture our products and to produce our product candidates.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
F. Hoffmann-La Roche Ltd
“Contract manufacturing revenue increased by $75.0 million primarily due to increased deliveries of ELEVIDYS to Roche in 2025 and increases in our manufacturing costs driven by greater-than-expected write-offs of (1) batches of our products not meeting our quality specifications as well as (2) certain excess or obsolete inventory attributable to Roche during 2025.”
Cited →
Its suppliers
Arrowhead Pharmaceuticals, Inc.
“As of September 30, 2025, the Company recorded $ 696.8 million in revenue from Sarepta and $ 6.8 million in accounts receivable.”
Cited →Nationwide Children's Hospital
“Nationwide may also terminate the Nationwide License Agreement under specified circumstances if we pursue litigation against Nationwide.”
Cited →“Beginning July 1, 2022, pursuant to the 2021 Amendment, the BioMarin Parties were eligible to receive royalties of 4% in the U.S. and 5% outside the U.S. of net sales of Products covered by a Licensed Patent on a product-by-product and country-by-country basis.”
Cited →Catalent, Inc.
“In October 2025, we notified Catalent of our intention to release Catalent from its obligation to dedicate clean room suites to us, effective in the fourth quarter of 2026.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch